Dong-A ST Co., Ltd. (KRX:170900)

Market Cap	307.59B -30.8%
Revenue (ttm)	830.27B +14.6%
Net Income	-11.76B
EPS	-1,221.40
Shares Out	9.61M
PE Ratio	n/a
Forward PE	12.64
Dividend	666.67 (2.08%)
Ex-Dividend Date	Mar 10, 2026

Volume	22,724
Open	33,500
Previous Close	33,500
Day's Range	31,600 - 33,500
52-Week Range	31,600 - 56,381
Beta	0.38
Analysts	Buy
Price Target	60,761.90 (+89.88%)
Earnings Date	Jul 28, 2026

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 1,679
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2025, Dong-A ST's revenue was 808.78 billion, an increase of 15.89% compared to the previous year's 697.87 billion. Losses were -28.59 billion, 2237.8% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for 170900 stock is "Buy." The 12-month stock price target is ₩60,762, which is an increase of 89.88% from the latest price.

Price Target

₩60,762

(89.88% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 28, 2026

Data Sources Report a data error